OBJECTIVES: To perform an economic evaluation of Puregon Pen and the conventional syringe system with menotropin in the treatment of IVF/ICSI by comparing the process-utilities and the costs for the current Dutch situation. METHODS: A conjoint analysis (CA) was performed to express the preference of women for the different administration forms of FSH as process-utilities ranging from 0 to 1. In the CA, women were asked to give their preference for the different administration forms that were described by the levels of five attributes. A decision analytic model was developed to estimate the costs of an average IVF cycle in the Netherlands from the societal perspective. Epidemiologic and costing data were drawn from the available literature or were provided by experts. RESULTS: The process-utility was estimated to be 2.6 (p<0.05) higher for Puregon Pen compared to the conventional syringe containing menotropin. On a scale from 0 to 1, the process-utility was 0.96 (CI between 0.94 and 0.97) for Puregon Pen and 0.36 (CI: 0.30-0.46) for the conventional syringe, resulting in an incremental process-utility between 0.57 and 0.61. The additional costs per cycle for this increase are estimated to be €60-194. CONCLUSIONS: Compared with the conventional menotropin administration form, the added value of Puregon Pen was 2.6 times higher at an extra cost per cycle of €60-194. The comparison shows that the utility-gain is substantial and that the additional costs are minimal. Therefore, it can be concluded that Puregon Pen is a cost-effective administration form.